Blood Cancer &
 Leukemia

Leukemia Cancer News - Return to Menu

Experimental drug stuns cancer doctors

ORLANDO (AP) 5/16/2005 - No one could have been more surprised than the doctors themselves.

They were just hoping to relieve the symptoms of a deadly blood disorder and ended up treating the disease itself. In nearly half of the people who took the experimental drug, the cancer became undetectable.

Specialists said Revlimid now looks like a breakthrough and the first effective treatment for many people with myelodysplastic syndrome, or MDS, which is even more common than leukemia.

"It may be, if not eradicating the disease, putting it into what I would call deep remission," said Dr. David Johnson, a cancer specialist at Vanderbilt-Ingram Cancer Center who is familiar with but had no role in the research.

Revlimid "is not yet on the market but almost certainly will be" because of these findings, he said.

MDS refers to a group of disorders caused by the bone marrow not making enough healthy, mature blood cells. About 15,000 to 20,000 new cases are diagnosed each year in the United States, and as many as 50,000 Americans have it now. They usually suffer anemia and fatigue and need blood transfusions about every eight weeks to stay alive.

"It's a serious problem, it tends to occur in older people, and it's fatal for most," said Dr. Herman Kattlove, a blood disorder specialist at the American Cancer Society.

Revlimid is similar to thalidomide, a drug notorious for the birth defects it caused decades ago but that in recent years has proved effective against another blood cancer, multiple myeloma. Researchers don't really know how it works other than that it boosts the immune system in a number of ways.

In small studies, Revlimid also showed promise and with far fewer side effects. In a new study, doctors tested it on 115 people with MDS who have the most common chromosome abnormality that causes the disease.

After about six months on the drug, 66% no longer needed blood transfusions, said the study's leader, Dr. Alan List of the H. Lee Moffitt Cancer Center in Tampa A year later, three-fourths of them still don't need transfusions.

But the big surprise was that signs of the genetic mutation fueling the disease diminished in 81 patients and vanished in 51.

"The chromosome abnormality completely disappeared, something we've never seen before" from a drug aimed just at boosting red blood cells, List said.

Dr. Bruce Johnson of the Dana-Farber Cancer Institute in Boston compared it with what doctors saw in early tests of the drug Gleevec on people with chronic myelogenous leukemia several years ago.

"If you extrapolate what they saw, it's one of the signs for long remission," he said of the abnormality's disappearance.

Dr. Jasmine Zain, a blood specialist from the City of Hope Cancer Center in New York, said the results warrant further testing on the drug.

"Nowhere do you see 60 to 70% responses," she said.

About one-third of people on the drug had temporary drops in other blood cells and clotting components, fixed by briefly interrupting treatment or lowering the dose.

The study was sponsored by Celgene Corp., which makes Revlimid. List is a consultant for the company and reported results Sunday at a meeting of the American Society of Clinical Oncology in Orlando.

In other news at the conference:

" A five-year study of cancer care in America concluded that most people get good care but that quality differs from region to region.

The oncology society commissioned the study by Harvard University and the RAND Corporation after a 2000 Institute of Medicine report said that not all Americans were getting good cancer care and that this seemed to be a substantial problem.

Researchers measured more than 100 factors affecting breast and colon cancer care, such as whether women were appropriately prescribed tamoxifen and whether radiation doses were correct. They concluded that 86% of people with breast cancer and 78% with colon cancer got good care, higher than what other studies have found for other diseases.

However, "these numbers range all over the place" for the five cities studied Atlanta, Cleveland, Houston, Kansas City and Los Angeles said Dr. Ezekiel Emanuel, a National Institutes of Health physician who headed the study. (Individual measures for each city were not released).

" Another study found that surgery and follow-up tests for stomach cancer are inadequate in most U.S. hospitals. Three out of four patients don't have enough lymph nodes removed to check for cancer, and this made a big impact on survival rates, said Dr. Natalie Coburn of Princess Margaret Hospital in Toronto who used a federal cancer database for her study.

Five-year survival was more than twice as high in Hawaii than in Utah, where surgery was poorest.

"I'm not suggesting you fly from Utah to Hawaii to have your surgery done," but patients need to know the qualifications of their surgeon, said Dr. David Johnson, who is president of the oncology society.

"If that's true for gastric cancer, we know it's true for other cancers like lung surgery, breast surgery and the like," he added.

Nearly 22,000 new cases of stomach cancer and 11,550 deaths are expected in the United States this year.

Celgene's Revlimid Effective vs. Blood Cancer

By Althea Chang
TheStreet.com Staff Reporter
5/16/2005 2:31 PM EDT

ORLANDO, Fla. -- Celgene's (CELG:Nasdaq - commentary - research) experimental drug Revlimid can eliminate a genetic abnormality causing the most common blood cancer, researchers announced at this year's annual meeting of the American Society of Clinical Oncology.

Revlimid helped patients with myelodysplastic syndromes reduce the need for transfusions and lower or even eliminate the genetic abnormality related to the disease, according to results presented by medical researchers at one of the most important medical meetings of the year.

In the study, 146 patients with MDS who relied on blood transfusions took 10 milligrams of Revlimid daily. After 24 weeks, 64% of patients did not need a transfusion. Of those patients, 76% saw a reduction in the number of bone marrow cells with a specific abnormality caused by the disease, and 55% had no evidence of the abnormality.

Myelodysplastic syndromes are blood disorders that cause low blood cell count due to improper blood cell development. The syndromes can lead to fatal bone marrow failure and acute leukemia.

Revlimid modifies or regulates immune system function and appears to kill certain cancer cells, stop inflammation and improve the function of the immune cells.

" [This product] is a breakthrough for patients with MDS," says Dr. Alan List, a professor at the Lee Moffitt Cancer Center and lead author of the study. "This is the first effective therapy for this specific subtype of the disease."

Celgen previously reported a positive phase III assessment in the treatment of multiple myeloma, based on a review by the monitoring committee on patients receiving Revlimid plus the steroid dexamethasone compared with patients receiving dexamethasone alone.

In March, the Summit, N.J., company allowed all patients in both studies access to Revlimid. The drug has received fast-track status from the Food and Drug Administration, and some analysts expect it to be on the market in early 2006.

Site Map | Acute Myelogenous Leukemia